Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- Check4 days agoChange DetectedThe page now indicates the trial is no longer recruiting and adds user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention/Treatment heading formatting is adjusted and the revision note updated from v3.5.5 to v3.6.0.SummaryDifference0.3%

- Check11 days agoChange DetectedNew revision history entries were added for 2026-06-01 and 2026-05-28 with Revision: v3.5.5, and older revision entries (2026-05-26, 2026-05-27) along with Revision: v3.5.4 were removed.SummaryDifference0.1%

- Check19 days agoChange DetectedAdds update-date entries (2026-05-27, 2026-05-26, 2026-05) and removes the Recruitment status and study contact details from the page, reducing visibility of current enrollment and direct contact options for potential participants.SummaryDifference4%

- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now shows the study as Active, not recruiting; it adds widened ILD/history exclusions and specifies contraception durations for R-Dx-d as 150 days during treatment and 210 days after the last dose.SummaryDifference0.6%

- Check55 days agoChange DetectedClinicalTrials.gov’s page software revision label was updated from v3.5.2 to v3.5.3, indicating a minor platform/version maintenance change.SummaryDifference0.0%

- Check62 days agoChange DetectedRecruitment status updated to Completed on 2026-04-13. The revision was updated to v3.5.2, replacing the earlier v3.5.0 entry.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.